US · Healthcare · Drug Manufacturers - General
EPS came in at 2.59 against a street estimate of 2.53 — a beat of 2.4%.
Analysts rate Johnson & Johnson a buy (16 buy, 6 hold, 1 sell out of 23) with an average price target of $279.41.
CONFIDENT J&J reported strong Q3 sales growth, raised 2026 revenue and EPS guidance, and highlighted powerful Innovative Medicine momentum despite MedTech weakness and major litigation and deal costs. Q3 FY26 Worldwide sales increased 6%; U.S. growth significantly outpaced international growth. Analysts pressed management on the sustainability of growth, ICO Tide adoption, international MedTech weakness and potential M&A. Management emphasized internal investment, stronger execution and existing portfolio potential. 2026-10-13…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.80% |
| Vanguard Capital Management, LLC | 6.52% |
| State Street Corp | 5.55% |
| Vanguard Portfolio Management, LLC | 2.67% |
| Geode Capital Management, LLC | 2.45% |
| JPMorgan Chase & Co | 2.42% |
| Morgan Stanley - Brokerage Accounts | 1.86% |
| NORGES BANK | 1.32% |
| Document | Date |
|---|---|
| Results announced · Q3 FY2027 HEADLINE NUMBERS • Third-quarter worldwide sales rose 5.9% to $25,399 million from $23,993 million; operational growth was 6.0%. • Nine-month worldw | 2026-10-13 |
| Board / officer change · Q3 FY2027 JOHNSON & JOHNSON FORM 8-K SUMMARY Filed August 4, 2026 --- OTHER NOTABLE POINTS • Executive Leadership Change: Jennifer Taubert announced retireme | 2026-08-04 |
| Reg FD disclosure · Q2 FY2027 JOHNSON & JOHNSON (JNJ) - FORM 8-K SUMMARY Filed: July 29, 2026 --- HEADLINE NUMBERS • 2026 Adjusted Operational EPS guidance reduced to $10.86-$11 | 2026-07-29 |
| Reg FD disclosure · Q2 FY2027 JOHNSON & JOHNSON FORM 8-K SUMMARY July 27, 2026 --- HEADLINE NUMBERS • $5.5 billion total commitment to resolve ovarian talc litigation • $3 billi | 2026-07-28 |
| Quarterly report · Q2 FY2027 JOHNSON & JOHNSON Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Sales (6 months): $49,372 million (up 8.2% vs. $45,636 million prior year) • Sales (Q2): $ | 2026-07-23 |
| Results announced · Q2 FY2027 JOHNSON & JOHNSON Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 Worldwide Sales: $25,310 million (up 6.6% reported, 5.6% operational) • Six-M | 2026-07-15 |
| Quarterly report · Q1 FY2027 JOHNSON & JOHNSON Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Q1 2026 Sales: $24,062 million, up 9.9% from $21,893 million in Q1 2025 • Q1 2026 Net Earn | 2026-04-22 |
| Proxy statement · Q1 FY2027 JOHNSON & JOHNSON 2026 PROXY STATEMENT SUMMARY --- CEO TOTAL COMPENSATION & CHANGE Joaquin Duato, Chairman and CEO: - 2025 total direct compensatio | 2026-03-11 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $1.34 / share ex-date Nov 24, 2026 · pay Dec 8, 2026 | 2026-11-24 |
| Dividend | $1.34 / share ex-date Aug 25, 2026 · pay Sep 8, 2026 | 2026-08-25 |
| Dividend | $1.34 / share ex-date May 26, 2026 · pay Jun 9, 2026 | 2026-05-26 |
| Dividend | $1.30 / share ex-date Feb 24, 2026 · pay Mar 10, 2026 | 2026-02-24 |
| Dividend | $1.30 / share ex-date Nov 25, 2025 · pay Dec 9, 2025 | 2025-11-25 |
| Announcement | Date |
|---|---|
| Completed acquisition of Firefly Bio and strategic collaboration with Sail Johnson & Johnson completed the acquisition of Firefly Bio and entered a strategic collaboration with Sail Biomedicines on July 29, 2026. These transactions require the company to lower its | 2026-07-29 |
| Board declares 3.1% dividend increase, 64th consecutive year Johnson & Johnson reported first-quarter 2026 results on April 14, 2026, and announced a 3.1% dividend increase. The company raised its quarterly dividend from $1.30 to $1.34 per share, brin | 2026-04-14 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Johnson & Johnson — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.